Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2005-06-21
2005-06-21
Chen, Shin-Lin (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S013000, C800S014000, C800S018000
Reexamination Certificate
active
06909030
ABSTRACT:
Disclosed is a null mutant (or knockout) rodent comprising in its germ cells an artificially induced PTTG null mutation. In some embodiments, the null mutant rodent can be generated by way of homologous recombination in an embryonic stem cell or germ cell. The inventive null mutant rodent can be used to study mammalian physiology at the cellular, tissue, and/or organismal level with respect to various phenotypes, including hyperglycemia, hypoinsulinaemia, hypoleptinemia, diabetes, chromosomal aneuploidy, premature centromere division, chromosomal damage, aberrant mitotic cellular division, thrombocytopenia, thymic hyperplasia, splenic hypoplasia, testicular hypoplasia, and female subfertility. Also disclosed is an animal model for diabetes. Also disclosed is a somatic or germ cell obtained from the null mutant rodent. Also disclosed is a cell line derived from a cell obtained from the null mutant rodent.
REFERENCES:
patent: 5684222 (1997-11-01), Mak
patent: 5714667 (1998-02-01), Waterhouse et al.
patent: 5814300 (1998-09-01), Scott et al.
patent: 5844107 (1998-12-01), Hanson et al.
patent: 5877302 (1999-03-01), Hanson et al.
patent: 5972900 (1999-10-01), Ferkol, Jr. et al.
patent: 5972901 (1999-10-01), Ferkol, Jr. et al.
patent: 6077835 (2000-06-01), Hanson et al.
patent: 6087555 (2000-07-01), Dunstan et al.
patent: 6136040 (2000-10-01), Ornitz et al.
patent: 7322892 (1995-12-01), None
patent: 9173053 (1997-07-01), None
patent: WO 90/09442 (1990-08-01), None
patent: WO 95/25809 (1995-09-01), None
patent: WO 98/22587 (1998-05-01), None
patent: WO 98/39412 (1998-09-01), None
Wu et al., Methods in Gene Biotechnology, 1997, CRC Press, Boca Raton, p. 339-365.
Houdebine, Louis-Marie, 1994, Journal of Biotechnology, vol. 34, p. 269-287.
Sigmund, C., 2000, Arterioscler Thromb Vasc Biol., vol. 20, p. 1425-1429.
Seamark, R. F., 1994, Reprod. Fertil. Dev., vol. 6, p. 653-657.
Wolfer et al., 2002, Trends in Neurosciences, vol. 25, No. 7, p. 336-340.
Marra, M., et al., “The WashU-HHMI Mouse EST project, AC W81747”, EMBL Database, Jun. 27, 1996, Heidelberg, XP002066845.
Hillier, L., et al., The WashU-Merck EST project, AC AA007646, EMBL Database, Jul. 28, 1996, Heidelberg, XP002066846.
Holton, T., et al., “ACQ57612”, EMBL Database, Sep. 5, 1994, Heidelberg, XP002066847.
Nippon Telegraph and Telephone Corp.: “ACQ75553”, EMBL Database, Aug. 4, 1995, Heidelberg, XP002066848.
Gonsky, R., et al., “Transforming DNA Sequences Present in Human Prolactin-Secreting Pituitary Tumors”, Molec. Endocrin., 5(11): 1687-1695, Nov. 1991.
Pei, L., et al., “Isolation and Characterization of a Pituitary Tumor-Transforming Gene (PTTG)”, Molec. Endocrin., 11(4): 433-441, Apr. 1997.
Shimon, I., et al., “Genetic Basis of Endocrine Disease”, J. Clin. Endocrin. And Metab., 82(6): 1675-1681, Jun. 1997.
Chen, L., et al., “Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization.”, 1: Gene 2000, May 2; 248 (102): 41-50.
Heaney, A.P., “Expression of pituitary-tumor transforming gene in colorectal tumours”, 1: Lancet 2000 Feb. 26; 355(9205):716-9.
Heaney, A.P., “Early Involvement of Estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis”, 1: Nat Med 1999, Nov; 5(11): 1317-21.
Suhardja, A.S., et al., “Molecular pathogenesis of pituitary adenomas: a review.”, Acta Neurochir (Wien) 1999; 141(7): 729-36. Abstract Only.
Ren, R., et al., “Identification of a ten-amino acid proline-rich SH3 binding site.”, Science 1993 Feb 19; 259(5098): 1157-61. Abstract Only.
Liu, X., et al., “The v-Src SH3 domain binds phosphatidylinositol 3′-kinase.”, Mol Cell Biol 1993 Sep; 13(9): 5225-32. Abstract Only.
Gout, I., et al., “The GTPase dynamin binds to and is activated by a subset of SH3 domains.” Cel 1993 Oct 8; 75(1): 25-36.
Yu, H., et al., “Solution structure of the SH3 domain of Src and identification of its ligan-binding site.” Science 1992 Dec 4; 258(5088): 1665-8. Abstract Only.
Lee, I.A., et al., “Cloning and expression of human cDNA encoding human homologue of pituitary tumor transforming gene.”, Biochem Mol. Biol Int 1999 May; 47(5): 891-7. Abstract Only.
Zou, H., et al., “Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis.”, Science 1999 Jul 16; 285(5426): 418-22. Abstract Only.
Zhang, X., et al., “Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.” J Clin Endocrinol Metab 1999 Feb; 84(2): 761-7.
Prezant, T.R., et al., “An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors; evidence fo hPTTG family.”, J Clin Endocrinol Metab 1999 Mar; 84(3): 1149-52.
Fujimoto, N., et al., “Establishment of an estrogen responsive rat pituitary cell sub-line MtTE-2.” Endocr J 1999 Jun.; 46(3): 389-96. Abstract Only.
Ramos-Morales, F., et al., “Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product.”, Oncogene 2000 Jan 20; 19(3): 403-9. Abstract Only.
McCabe C.J., et al., “PTTG—a new pituitary tumour transforming gene.”, J Endocrinol 1999 Aug; 162(2): 163-6.
Kakar, S.S., “Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene (PTTG).”, Gene 1999 Nov 29; 240(2): 317-24. Abstract Only.
Dominguez, A., et al., “hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG.”, Oncogene 1998 Oct 29; 17(17): 2187-93. Abstract Only.
Pei, L., “Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells.”, J Biol Chem 1999 Jan 29; 274(5): 3151-8.
Saez, C., et al., “hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias.”, Oncogene 1999 Sep 23; 18(39): 5473-6. Abstract Only.
Pei, L., “Genomic Organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene.”, J Biol Chem 1998 Feb 27; 273(9): 5219-25.
Wang, Z., et al., “Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter.”, Endocrinology 2000 Feb; 141(2): 763-71.
Zhang, X., et al., “Structure, expression, and function of human pituitary tumor-transforming gene (PTTG).”, Mol Endocrinol 1999 Jan; 13(1): 156-66.
Heaney, Anthony, P., et al., “Pituitary tumor transforming gene: a novel factor in pituitary tumour formation,” Balliere's Clinical Endocrinology and Metabolism, vol. 13, No. 3, pp. 367-380, 1999.
Krieger, N.R., et al.,Rat pancreatic islet and skin xenograft survival in CD4 and CD8 knockout mice, J. Autoimmun.,10(3):309-15 (Jun 1997). Abstract Only.
Wang, Z., et al.,Pituitary tumor transforming gene(PTTG)transforming and transactivation activity, J. Biol. Chem.,275(11):7459-61 (Mar 17, 2000).
Dubik, D., et al.,Mechanism of estrogen activation of c-myc oncogene expression, Oncogene,7(8):1587-94 (Aug 1992). Abstract Only.
Farrell, W.E.,Molecular Pathogenesis of Pituitary Tumors, Front Neuroendocrinol.,21(3):174-198 (Jul 2000). Abstract Only.
Pei, L.,Activation of mitogen-activated kinase cascade regulates pituitary tumor-transforming gene transactivation function, J. Biol. Chem.275(40):31191-8 (Oct 6, 2000). Abstract Only.
Shepel, L.A., et al.,Relationship of polymorphisms near the rat prolactin, N-ras, and retinoblastoma genes with susceptibility to estrogen-induced pituitary tumors, Cancer Res.,50 (24):7920-5 (Dec 15, 1990). Abstract Only.
Sutherland, R.L, et al.,Estrogen and progestin regulation of cell cycle progression, J. Mammary Gland Bi
Melmed Shlomo
Wang Zhi-yong
Cedars-Sinai Medical Center
Chen Shin-Lin
Davis , Wright, Tremaine, LLP
Levy Seth D.
LandOfFree
PTTG knockout rodent as a model to study mechanisms for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PTTG knockout rodent as a model to study mechanisms for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PTTG knockout rodent as a model to study mechanisms for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3493686